Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29938335 | 1.00 | MAPT (0.45) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL27411079 | 0.91 | POLB (0.40) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL4429339 | 0.88 | MAPT (0.44) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL27410901 | 0.87 | MEN1 (0.42) | MEN1KMT2ACYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4423888 | 0.86 | POLB (0.47) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL4433270 | 0.84 | MEN1 (0.42) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL4428097 | 0.83 | NPC1 (0.44) | POLBMEN1KMT2ANPSR1GAA | |
| SCHEMBL4435048 | 0.78 | MAPT (0.40) | MAPTPOLBMEN1KMT2ANPSR1 | |
| SCHEMBL4434995 | 0.77 | MAPT (0.44) | MAPTPOLBLMNA | |
| SCHEMBL4426588 | 0.76 | MAPT (0.42) | MAPTPOLBMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217997-A1 | NOVEL MEPICIDES AS ANTIMICROBIAL AGENTS | GEORGE MASON UNIVERSITY | 2024-07-04 | — | — | US | disclosed |
| US-20240217997-A1 | NOVEL MEPICIDES AS ANTIMICROBIAL AGENTS | GEORGE MASON UNIVERSITY | 2024-07-04 | — | — | US | disclosed |
| US-7638505-B2 | Organophosphoric derivatives useful as anti-parasitic agents | UNIVERSITEIT GENT (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20080312190-A1 | Such as 3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid; Antimalaria agents | UNIVERSITEIT GENT (BE) | 2008-12-18 | — | — | US | disclosed |
| EP-1963344-A1 | ORGANOPHOSPHORIC DERIVATIVES USEFUL AS ANTI-PARASITIC AGENTS | UNIVERSITEIT GENT (BE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007071453-A1 | ORGANOPHOSPHORIC DERIVATIVES USEFUL AS ANTI-PARASITIC AGENTS | UNIVERSITEIT GENT (BE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217997-A1 | NOVEL MEPICIDES AS ANTIMICROBIAL AGENTS | SMPD1, MLYCD, SMPD3 | MAPT 4119/4885POLB 994/4885MEN1 4603/4885 |
| US-20080312190-A1 | Such as 3-(N-hydroxyacetamido)-1-(3,4-dichlorophenyl)propylphosphonic acid; Antimalaria agents | SUB1, CBR1, NAT1 | MAPT 4756/4885POLB 1824/4885MEN1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.